{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:45:35Z","timestamp":1792097135510,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126174","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:28:24Z","timestamp":1789860504000},"page":"126174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment patterns of oral corticosteroid and nonsteroidal immunosuppressant therapy and clinical outcomes in US patients receiving ravulizumab or eculizumab for generalized myasthenia gravis"],"prefix":"10.1016","volume":"491","author":[{"given":"Svetlana","family":"Faktorovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blackowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sabatella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Alpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2026.126174_bb0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol. Clin."},{"issue":"11","key":"10.1016\/j.jns.2026.126174_bb0010","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jns.2026.126174_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-190464","article-title":"Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: a case series","volume":"7","author":"Datta","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"10.1016\/j.jns.2026.126174_bb0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.jns.2026.126174_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2025.101969","article-title":"Myasthenia gravis: mechanisms, clinical syndromes, and diagnosis","volume":"71","author":"Fecto","year":"2025","journal-title":"Dis. Mon."},{"issue":"10","key":"10.1016\/j.jns.2026.126174_bb0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2026.126174_bb0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","article-title":"Myasthenia gravis\u2014pathophysiology, diagnosis, and treatment","volume":"200","author":"Tannemaat","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0045","series-title":"Emerging Drugs for Generalized Myasthenia Gravis: CADTH Horizon Scan","author":"Ndegwa","year":"2022"},{"key":"10.1016\/j.jns.2026.126174_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839075","article-title":"A randomized open-labeled trial of methotrexate as a steroid-sparing agent for patients with generalized myasthenia gravis","volume":"13","author":"Di","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.jns.2026.126174_bb0060","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0065","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126174_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.jns.2026.126174_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14712598.2023.2185131","article-title":"Ravulizumab for the treatment of myasthenia gravis","volume":"23","author":"Vanoli","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jns.2026.126174_bb0080","series-title":"StatPearls","article-title":"Corticosteroid Adverse Effects","author":"Yasir","year":"2025"},{"issue":"4","key":"10.1016\/j.jns.2026.126174_bb0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126174_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1625457","article-title":"Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the medical data vision database in Japan","volume":"16","author":"Teranishi","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.125716","article-title":"Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network","volume":"481","author":"Qi","year":"2026","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.126174_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000512077","article-title":"Exacerbation rate in generalized myasthenia gravis and its predictors","volume":"84","author":"Abuzinadah","year":"2021","journal-title":"Eur. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126174_bb0110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126174_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.767961","article-title":"Patients with myasthenia gravis with acute onset of dyspnea: predictors of progression to myasthenic crisis and prognosis","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"issue":"2","key":"10.1016\/j.jns.2026.126174_bb0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11940-005-0022-2","article-title":"An update on myasthenic crisis","volume":"7","author":"Ahmed","year":"2005","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0130","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251332037","article-title":"Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis","volume":"18","author":"Marini","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jns.2026.126174_bb0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126174_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251398375","article-title":"Appropriate use of steroids for patients with generalized myasthenia gravis: an international Delphi study","volume":"18","author":"Wiendl","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.jns.2026.126174_bb0145","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1007\/s00415-024-12569-w","article-title":"United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use","volume":"271","author":"Habib","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1378080","article-title":"Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"15","author":"Katyal","year":"2024","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126174_bb0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2026.126174_bb0160","article-title":"Concomitant immunosuppressive therapy use with ravulizumab: analysis of a generalized myasthenia gravis global registry [abstract EPR-297]","volume":"32","author":"Nowak","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126174_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0170","series-title":"Oral corticosteroid use in US patients with generalized myasthenia gravis (gMG) receiving complement C5 or neonatal Fc receptor inhibitors [poster P369], presented at: Annual Clinical and Scientific Conference of the Muscular Dystrophy Association","author":"Silvestri","year":"2025"},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40120-025-00873-0","article-title":"Oral corticosteroid and nonsteroidal immunosuppressant therapy use in patients with myasthenia gravis receiving ravulizumab, eculizumab, or efgartigimod in the USA","volume":"15","author":"Sacc\u00e0","year":"2026","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2026.126174_bb0180","author":"PharMetrics Plus Fact Sheet"},{"key":"10.1016\/j.jns.2026.126174_bb0185","author":"PharMetrics Plus for Academics Fact Sheet"},{"key":"10.1016\/j.jns.2026.126174_bb0190","series-title":"Soliris (eculizumab) [prescribing information]","year":"2025"},{"key":"10.1016\/j.jns.2026.126174_bb0195","author":"Soliris (eculizumab)"},{"key":"10.1016\/j.jns.2026.126174_bb0200","series-title":"Ultomiris (ravulizumab) [prescribing information]","year":"2025"},{"key":"10.1016\/j.jns.2026.126174_bb0205","author":"Ultomiris (ravulizumab)"},{"key":"10.1016\/j.jns.2026.126174_bb0210","series-title":"Zilbrysq (zilucoplan) [prescribing information]","year":"2025"},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.jns.2026.126174_bb0220","series-title":"Endotext [Internet]","article-title":"Glucocorticoid therapy and adrenal suppression","author":"Nicolaides","year":"2000"},{"issue":"7 Suppl 1","key":"10.1016\/j.jns.2026.126174_bb0225","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1212\/WNL.0000000000205166","article-title":"Comorbidity burden and steroid use in generalized myasthenia gravis: a retrospective analysis of Medicare fee-for-service claims [abstract P4\u201311.015]","volume":"102","author":"Blackowicz","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126174_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117549","article-title":"Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy","volume":"427","author":"Laakso","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2026.126174_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2025.104956","article-title":"The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: a patient-reported survey analysis","volume":"411-412","author":"Yan","year":"2025","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jns.2026.126174_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0250","series-title":"Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: A retrospective analysis of registry data [poster 1.5-002] presented at: Annual Meeting of the American Academy of Neurology","author":"Pulley","year":"2023"},{"issue":"4","key":"10.1016\/j.jns.2026.126174_bb0255","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40801-024-00457-8","article-title":"US clinical practice experience with eculizumab in myasthenia gravis: acute clinical events and healthcare resource utilization","volume":"11","author":"Nowak","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jns.2026.126174_bb0260","unstructured":"M. Takahashi, M. Masuda, M. Watanabe, et al., Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Effectiveness, concomitant oral corticosteroid use and safety data from post-marketing surveillance [poster EPO-396], Presented at: Annual Meeting of the European Academy of Neurology, Budapest, Hungary, July 1-4, 2023."},{"issue":"3","key":"10.1016\/j.jns.2026.126174_bb0265","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/mus.27656","article-title":"Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Muscle Nerve"},{"issue":"18 Suppl","key":"10.1016\/j.jns.2026.126174_bb0270","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1212\/WNL.98.18_supplement.868","article-title":"Real-world eculizumab effectiveness on US patient outcomes in myasthenia gravis (ELEVATE): a retrospective chart review [abstract S41.010]","volume":"98","author":"Habib","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2026.126174_bb0275","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2026.126174_bb0280","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J. Neurol."},{"issue":"7 Suppl 1","key":"10.1016\/j.jns.2026.126174_bb0285","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1212\/WNL.0000000000208774","article-title":"Long-term effectiveness and safety of eculizumab in patients with generalized myasthenia gravis (gMG): real-world data from Japan [abstract S34.006]","volume":"104","author":"Murai","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126174_bb0290","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ensci.2019.01.006","article-title":"Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: a case report","volume":"14","author":"Amano","year":"2019","journal-title":"eNeurologicalSci"},{"issue":"11","key":"10.1016\/j.jns.2026.126174_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.9547","article-title":"Two-decade battle with myasthenia gravis: a breakthrough case report on the long-term success with eculizumab and ravulizumab treatment","volume":"12","author":"Quasthoff","year":"2024","journal-title":"Clin. Case Rep."},{"issue":"5","key":"10.1016\/j.jns.2026.126174_bb0300","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."},{"issue":"12","key":"10.1016\/j.jns.2026.126174_bb0305","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16490","article-title":"Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"31","author":"Habib","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2026.126174_bb0310","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126174_bb0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jns.2026.126174_bb0320","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/acn3.52051","article-title":"Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis","volume":"11","author":"Tokuyasu","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2026.126174_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123628","article-title":"First analysis of the myasthenia gravis SPOTLIGHT registry: outcomes with eculizumab and ravulizumab","volume":"476","author":"Howard","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2026.126174_bb0330","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00415-025-13127-8","article-title":"Ravulizumab for generalized myasthenia gravis: a multicenter real-life experience","volume":"272","author":"Rossini","year":"2025","journal-title":"J. Neurol."},{"issue":"7 Suppl 1","key":"10.1016\/j.jns.2026.126174_bb0335","article-title":"Assessment of hospitalizations in patients with generalized myasthenia gravis (gMG) before and during treatment with ravulizumab: results from a global registry [abstract P1-11.016]","volume":"104","author":"Tandan","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126174_bb0340","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in myasthenia gravis: a review of the current evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jns.2026.126174_bb0345","author":"Nowak","year":"2024"},{"issue":"2","key":"10.1016\/j.jns.2026.126174_bb0350","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/ddc3020018","article-title":"Zilucoplan: a newly approved macrocyclic peptide for treatment of anti-acetylcholine receptor positive myasthenia gravis","volume":"3","author":"Costa","year":"2024","journal-title":"Drugs Drug Candidates"},{"key":"10.1016\/j.jns.2026.126174_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123652","article-title":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","volume":"477","author":"Goyal","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.126174_bb0360","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2026.126174_bb0365","author":"Yungher","year":"2025"},{"key":"10.1016\/j.jns.2026.126174_bb0370","unstructured":"A study to investigate OCS tapering in adult participants with generalized myasthenia gravis treated with ravulizumab (OCTAGON) [NCT07221838], https:\/\/clinicaltrials.gov\/study\/NCT07221838. Accessed October 31, 2025."},{"issue":"12","key":"10.1016\/j.jns.2026.126174_bb0375","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000047979","article-title":"Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: a retrospective claims-based analysis","volume":"105","author":"Silvestri","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jns.2026.126174_bb0380","unstructured":"Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. Guidance for industry, https:\/\/www.fda.gov\/media\/152503\/download. Accessed September 30, 2025."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:04:15Z","timestamp":1792094655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":76,"alternative-id":["S0022510X26004569"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126174","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns of oral corticosteroid and nonsteroidal immunosuppressant therapy and clinical outcomes in US patients receiving ravulizumab or eculizumab for generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126174"}}